These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15896360)

  • 1. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.
    Baumhaekel M; Scheffler P; Boehm M
    Microvasc Res; 2005 May; 69(3):178-9. PubMed ID: 15896360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL
    Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].
    Rosenkranz S; Caglayan E; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
    Dtsch Med Wochenschr; 2004 Aug; 129(33):1736-40. PubMed ID: 15295684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon.
    Kamata Y; Minota S
    Rheumatol Int; 2014 Nov; 34(11):1623-6. PubMed ID: 24789669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
    Roustit M; Blaise S; Allanore Y; Carpentier PH; Caglayan E; Cracowski JL
    Ann Rheum Dis; 2013 Oct; 72(10):1696-9. PubMed ID: 23426043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
    Govier F; Potempa AJ; Kaufman J; Denne J; Kovalenko P; Ahuja S
    Clin Ther; 2003 Nov; 25(11):2709-23. PubMed ID: 14693299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
    Eardley I; Mirone V; Montorsi F; Ralph D; Kell P; Warner MR; Zhao Y; Beardsworth A
    BJU Int; 2005 Dec; 96(9):1323-32. PubMed ID: 16287454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
    Anderson PC; Gommersall L; Hayne D; Arya M; Patel HR
    Expert Opin Pharmacother; 2004 Nov; 5(11):2241-9. PubMed ID: 15500370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
    Bischoff E
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S11-4. PubMed ID: 15224129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.
    Friedman EA; Harris PA; Wood AJ; Stein CM; Kurnik D
    Clin Pharmacol Ther; 2007 Apr; 81(4):503-9. PubMed ID: 17301734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.